Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01448850 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 464
- Enrollment target
NCT01448850 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 464 participants.
The verdict
NCT01448850, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 464 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease - GOLD stage II-IV) receiving standard maintenance therapy for the underlying disease condition.
Interventions
- OTHER Placebo
- BIOLOGICAL MEDI8968 600 mg IV, 300 mg SC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 464 participants |
| Start Date | 2011-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01448850
The ClinicalTrials.gov registry entry for NCT01448850 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 464 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01448850 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01448850 about?
NCT01448850 is a clinical study titled "A Study to Evaluate the Efficacy of MEDI8968 in Chronic Obstructive Pulmonary Disease". The purpose of this study is to evaluate the effect of MEDI8968 on the rate of moderate or severe acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in adult subjects with symptomatic, moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease - GOLD stag...
What is the current status of trial NCT01448850?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 464 participants. The study started on 2011-11. Estimated completion is 2014-02.
What interventions are being tested in trial NCT01448850?
The interventions under investigation include: Placebo (OTHER), MEDI8968 600 mg IV, 300 mg SC (BIOLOGICAL).
Who is sponsoring clinical trial NCT01448850?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.